1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Spinal Cord Injury - Pipeline Review, H2 2016

Spinal Cord Injury - Pipeline Review, H2 2016

  • November 2016
  • -
  • Global Markets Direct
  • -
  • 192 pages

Spinal Cord Injury - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury – Pipeline Review, H2 2016, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 23 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.Spinal Cord Injury.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Spinal Cord Injury - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Spinal Cord Injury Overview 8
Therapeutics Development 9
Pipeline Products for Spinal Cord Injury - Overview 9
Pipeline Products for Spinal Cord Injury - Comparative Analysis 10
Spinal Cord Injury - Therapeutics under Development by Companies 11
Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 14
Spinal Cord Injury - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Spinal Cord Injury - Products under Development by Companies 18
Spinal Cord Injury - Products under Investigation by Universities/Institutes 21
Spinal Cord Injury - Companies Involved in Therapeutics Development 22
AbbVie Inc 22
Acorda Therapeutics Inc 23
Asterias Biotherapeutics, Inc. 24
Asubio Pharma Co Ltd 25
Athersys Inc 26
BioArctic Neuroscience AB 27
BioAxone BioSciences Inc 28
Genervon Biopharmaceuticals LLC 29
Histocell SL 30
Kadimastem Ltd 31
Kringle Pharma Inc 32
Lpath Inc 33
MandalMed Inc 34
Mapreg SAS 35
Medgenics Inc 36
Neuralstem Inc 37
Neuronax SAS 38
New World Laboratories Inc 39
Omeros Corp 40
PharmatrophiX, Inc. 41
Pharmicell Co Ltd 42
Protagenic Therapeutics Inc. 43
Q Therapeutics Inc 44
Remedy Pharmaceuticals Inc 45
RespireRx Pharmaceuticals Inc 46
SanBio Inc 47
Stemedica Cell Technologies Inc 48
TissueGene Inc 49
TRB Chemedica International SA 50
Tumorend LLC 51
Vertex Pharmaceuticals Inc 52
Vicore Pharma AB 53
Spinal Cord Injury - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Target 56
Assessment by Mechanism of Action 59
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
(buspirone + carbidopa + levodopa) - Drug Profile 66
ABT-555 - Drug Profile 67
AP-325 - Drug Profile 68
APO-1 - Drug Profile 69
ASTOPC-1 - Drug Profile 70
AX-007 - Drug Profile 76
BA-277 - Drug Profile 77
BA-434 - Drug Profile 78
C-21 - Drug Profile 79
Cell Therapy for Spinal Cord Injury - Drug Profile 81
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 82
Cellgram-SCI - Drug Profile 83
CHEC-7 - Drug Profile 84
CHEC-9 - Drug Profile 85
chondroitinase ABC nanosphere - Drug Profile 86
CLR-01 - Drug Profile 87
CM-101 - Drug Profile 88
CX-717 - Drug Profile 89
Drug for Spinal Cord Injury - Drug Profile 91
FAB-117HC - Drug Profile 92
Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile 93
glyburide - Drug Profile 94
GM-603 - Drug Profile 97
HBN-1 - Drug Profile 98
ICCN-100 - Drug Profile 99
IMS-001 - Drug Profile 100
IMS-002 - Drug Profile 101
JM-4 - Drug Profile 102
KP-100IT - Drug Profile 103
LM11A-31BHS - Drug Profile 105
LPA-181 - Drug Profile 107
Lpathomab - Drug Profile 108
MAP-4343 - Drug Profile 111
Neu-2000 - Drug Profile 112
NeuroRelease SCI - Drug Profile 113
neurovitas - Drug Profile 114
NOVO-117 - Drug Profile 115
NSI-566 - Drug Profile 116
NWL-53 - Drug Profile 124
NX-210 - Drug Profile 125
Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile 126
PF-05285401 - Drug Profile 127
porcine GM1 ganglioside - Drug Profile 137
PT-00114 - Drug Profile 138
Q-Cells - Drug Profile 139
Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile 141
Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury - Drug Profile 142
SB-618 - Drug Profile 143
SB-623 - Drug Profile 144
SC-0806 - Drug Profile 148
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 149
Small Molecules for Spinal Cord Injury - Drug Profile 150
Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis - Drug Profile 151
Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 152
Stem Cell Therapy for CNS Disorders - Drug Profile 153
Stem Cell Therapy for Neurodegenerative Diseases - Drug Profile 154
Stem Cell Therapy for Spinal Cord Injury - Drug Profile 156
Stem Cell Therapy for Spinal Cord Injury - Drug Profile 157
Stem Cell Therapy for Spinal Cord Injury - Drug Profile 158
SUN-13837 - Drug Profile 159
Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile 160
Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile 161
TG-N - Drug Profile 162
UH-0113 - Drug Profile 163
UH-0213 - Drug Profile 164
VX-210 - Drug Profile 165
Spinal Cord Injury - Dormant Projects 168
Spinal Cord Injury - Discontinued Products 174
Spinal Cord Injury - Product Development Milestones 175
Featured News and Press Releases 175
Appendix 186
Methodology 186
Coverage 186
Secondary Research 186
Primary Research 186
Expert Panel Validation 186
Contact Us 186
Disclaimer 187

List of Tables
Number of Products under Development for Spinal Cord Injury, H2 2016 14
Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Development by Companies, H2 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Investigation by Universities/Institutes, H2 2016 26
Spinal Cord Injury - Pipeline by AbbVie Inc, H2 2016 27
Spinal Cord Injury - Pipeline by Acorda Therapeutics Inc, H2 2016 28
Spinal Cord Injury - Pipeline by Asterias Biotherapeutics, Inc., H2 2016 29
Spinal Cord Injury - Pipeline by Asubio Pharma Co Ltd, H2 2016 30
Spinal Cord Injury - Pipeline by Athersys Inc, H2 2016 31
Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H2 2016 32
Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, H2 2016 33
Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 34
Spinal Cord Injury - Pipeline by Histocell SL, H2 2016 35
Spinal Cord Injury - Pipeline by Kadimastem Ltd, H2 2016 36
Spinal Cord Injury - Pipeline by Kringle Pharma Inc, H2 2016 37
Spinal Cord Injury - Pipeline by Lpath Inc, H2 2016 38
Spinal Cord Injury - Pipeline by MandalMed Inc, H2 2016 39
Spinal Cord Injury - Pipeline by Mapreg SAS, H2 2016 40
Spinal Cord Injury - Pipeline by Medgenics Inc, H2 2016 41
Spinal Cord Injury - Pipeline by Neuralstem Inc, H2 2016 42
Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2016 43
Spinal Cord Injury - Pipeline by New World Laboratories Inc, H2 2016 44
Spinal Cord Injury - Pipeline by Omeros Corp, H2 2016 45
Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H2 2016 46
Spinal Cord Injury - Pipeline by Pharmicell Co Ltd, H2 2016 47
Spinal Cord Injury - Pipeline by Protagenic Therapeutics Inc., H2 2016 48
Spinal Cord Injury - Pipeline by Q Therapeutics Inc, H2 2016 49
Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals Inc, H2 2016 50
Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, H2 2016 51
Spinal Cord Injury - Pipeline by SanBio Inc, H2 2016 52
Spinal Cord Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2016 53
Spinal Cord Injury - Pipeline by TissueGene Inc, H2 2016 54
Spinal Cord Injury - Pipeline by TRB Chemedica International SA, H2 2016 55
Spinal Cord Injury - Pipeline by Tumorend LLC, H2 2016 56
Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 57
Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2016 58
Assessment by Monotherapy Products, H2 2016 59
Assessment by Combination Products, H2 2016 60
Number of Products by Stage and Target, H2 2016 62
Number of Products by Stage and Mechanism of Action, H2 2016 65
Number of Products by Stage and Route of Administration, H2 2016 68
Number of Products by Stage and Molecule Type, H2 2016 70
Spinal Cord Injury - Dormant Projects, H2 2016 173
Spinal Cord Injury - Dormant Projects (Contd..1), H2 2016 174
Spinal Cord Injury - Dormant Projects (Contd..2), H2 2016 175
Spinal Cord Injury - Dormant Projects (Contd..3), H2 2016 176
Spinal Cord Injury - Dormant Projects (Contd..4), H2 2016 177
Spinal Cord Injury - Dormant Projects (Contd..5), H2 2016 178
Spinal Cord Injury - Discontinued Products, H2 2016 179

List of Figures
Number of Products under Development for Spinal Cord Injury, H2 2016 14
Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Products, H2 2016 22
Assessment by Monotherapy Products, H2 2016 59
Number of Products by Top 10 Targets, H2 2016 61
Number of Products by Stage and Top 10 Targets, H2 2016 61
Number of Products by Top 10 Mechanism of Actions, H2 2016 64
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 64
Number of Products by Routes of Administration, H2 2016 67
Number of Products by Stage and Routes of Administration, H2 2016 67
Number of Products by Top 10 Molecule Types, H2 2016 69
Number of Products by Stage and Top 10 Molecule Types, H2 2016 69

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dystrophin (DMD) - Pipeline Review, H2 2016

Dystrophin (DMD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Dystrophin (DMD) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Dystrophin (DMD) - Pipeline Review, H2 2016’, provides in depth analysis on Dystrophin (DMD) targeted pipeline therapeutics. ...

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016’, provides in ...

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.